Abstract
Some reports have suggested that naloxone, a short-acting opiate receptor blocker given intravenously, has a beneficial effect on the symptoms of senile dementia of the Alzheimier type. We have performed a double-blind, crossover trial of naltrexone, an orally active, long acting opiate antagonist, in 17 Alzheimer-type dementia patients. None showed any improvement in assessments of day-to-day living skills or on a battery of neuropsychological tests. No side effects were noted. In the dosage used, naltrexone appears not to be useful in Alzheimer-type dementia.
Original language | English (US) |
---|---|
Pages (from-to) | 1169-1171 |
Number of pages | 3 |
Journal | Journal of Neurology, Neurosurgery and Psychiatry |
Volume | 48 |
Issue number | 11 |
DOIs | |
State | Published - 1985 |
All Science Journal Classification (ASJC) codes
- Surgery
- Clinical Neurology
- Psychiatry and Mental health